[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362393-105":59,"doc-detail-362393-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-long-term-survival-prediction-model-for-non-small-cell-lung-cancer-based-on-blood-inflammatory-biomarkers","A long-term survival prediction model for non-small cell lung cancer based on blood inflammatory biomarkers","","Background: Lung cancer remains a leading cause of cancer mortality and imposes major economic burden in China. A simple, efficient, and practical prognostic model is needed to support treatment planning and reduce costs while improving patients’ quality of life. Methods: Clinical characteristics and blood inflammatory biomarkers from 501 first-diagnosed NSCLC patients (June 2004–December 2016) were analyzed using group comparisons and LASSO-selected overall-survival predictors to build a BIB-based model. Results: Kaplan–Meier differences across clinical strata and BIB subgroups, with AUCs demonstrating predictive accuracy. Conclusion: The combined clinical-characteristics and BIB prognostic model is straightforward, efficient, and broadly applicable.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-long-term-survival-prediction-model-for-non-small-cell-lung-cancer-based-on-blood-inflammatory-biomarkers/362393/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-long-term-survival-prediction-model-for-non-small-cell-lung-cancer-based-on-blood-inflammatory-biomarkers/362393.png","ImageObject",300,407,{"name":92,"@type":93},"Rhys","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data and timeframe were used to build the survival prediction model?","Question",{"text":112,"@type":113},"The study collected clinical characteristics and blood inflammatory biomarkers from 501 patients with first-diagnosed NSCLC between June 2004 and December 2016.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were predictors selected for overall survival?",{"text":117,"@type":113},"Overall-survival-related factors were selected using LASSO regression, followed by establishing a prognostic model based on blood inflammatory biomarkers.",{"name":119,"@type":110,"acceptedAnswer":120},"How accurate was the model at predicting survival over different horizons?",{"text":121,"@type":113},"The blood inflammatory biomarker prognostic model showed good predictive value with AUCs of 0.811, 0.891, 0.856, and 0.841 for 1-year, 3-year, 5-year, and 10-year survival, respectively.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362393,1790998312,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Du et al. Discover Oncology (2026) 17:287 [https://doi.org/10.1007/s12672-026-04582-4](https://doi.org/10.1007/s12672-026-04582-4)  \nDiscover Oncology  \nRESEARCH Open Access  \nA long-term survival prediction model  for non-small cell lung cancer based on blood inflammatory biomarkers  \nYuxia Du1,2,3†, Weihong Qiu2†, Fei He2,4, Zhibin Zhou5 and Weimin Ye2,4,6*  \n†Yuxia Du and Weihong Qiu have contributed equally to this work.  \n*Correspondence: Weimin Ye [ywm@fjmu.edu.cn](ywm@fjmu.edu.cn)  \n1School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China  \n2Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, Fujian, China  \n3The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China  \n4Fujian Digital Tumor Data Research Center, Fuzhou, China 5Department of Respiratory and Critical Care Medicine, the Shishi Municipal Hospital, Shishi, Fujian, China  \n6Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden  \nAbstract  \nBackground Lung cancer with the highest incidence and mortality rates of malignant tumors in the world, has become one of the greatest economic burden diseases in China. To construct a simple, efficient, and practical prognostic model for lung cancer can accurately guide the development of treatment plans for patients without additional expenses, which is beneficial for reducing medical costs and improving patients’ quality of life.  \nMethods Clinical characteristics and blood inflammatory biomarkers (BIBs) of 501 patients diagnosed with NSCLC for the first time between June 2004 and December 2016 were collected. Group analyses were conducted on clinical characteristics and BIBs. Relevant factors for overall survival were selected using LASSO regression, and a prognostic model based on BIBs was established.  \nResults Kaplan–Meier analysis indicated statistically significant differences in lung cancer survival among subgroups of gender, smoking, pathological type, TNM  \nstage, surgical status, and Performance Status (PS) score (all P \u003C 0. 05), whereas no significant differences were observed among age and Charlson Comorbidity Index (CCI) subgroups (all P > 0. 05) . Statistically significant differences in lung cancer survival were also observed among subgroups of various BIBs (all P \u003C 0. 05) . The BIBs prognostic model demonstrated good predictive value with AUCs of 0 . 811, 0 . 891, 0 . 856, and 0.841 for 1-year, 3-year, 5-year, and 10-year survival, respectively, effectively predicting NSCLC prognosis.  \nConclusion The prognostic model based on clinical characteristics and BIBs exhibit simplicity, efficiency, and broad application prospects.  \nKeywords Non-small cell lung cancer, Blood inflammatory biomarkers, Nomograms, Survival  \n1 Introduction  \nLung cancer has become the most common cancer in terms of incidence and mortality [1]. It is estimated that the global economic cost of cancer from 2020 to 2050 will reach $25.2 trillion, equivalent to 0.55% of the global Gross Domestic Product. The  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to ob","cbCaijEHwwhgUp3G","https://ap.wps.com/l/cbCaijEHwwhgUp3G","pdf",3047186,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Lung cancer burden and need for prognostic tools\n## Blood inflammatory biomarkers as predictors\n## Rationale for integrating biomarkers with clinical characteristics","[{\"question\":\"What data and timeframe were used to build the survival prediction model?\",\"answer\":\"The study collected clinical characteristics and blood inflammatory biomarkers from 501 patients with first-diagnosed NSCLC between June 2004 and December 2016.\"},{\"question\":\"How were predictors selected for overall survival?\",\"answer\":\"Overall-survival-related factors were selected using LASSO regression, followed by establishing a prognostic model based on blood inflammatory biomarkers.\"},{\"question\":\"How accurate was the model at predicting survival over different horizons?\",\"answer\":\"The blood inflammatory biomarker prognostic model showed good predictive value with AUCs of 0.811, 0.891, 0.856, and 0.841 for 1-year, 3-year, 5-year, and 10-year survival, respectively.\"}]","A long-term survival prediction model for non-small cell lung cancer based on blood inflammatory biomarkers | PDF",1790147526,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45802ed8fcbba454baa1468fbfaf3868.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b89ea81babd1b76e1d020d5fb2e1fc27.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28984fd75ac5e07a5b76511e5c5cd6aa.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86c568a751ec26e21dea056c9c94431c.webp",980,1306]